Peer‑Reviewed and IP‑Protected Scientific Data

Supporting our Next‑Generation Parkinson’s Cell Therapy

UniPotent’s platform is built on over a decade of focused innovation in dopaminergic lineage engineering and is supported by high‑impact peer‑reviewed publications and proprietary intellectual property. Together, these studies establish a differentiated, scalable, and clinically translatable approach to Parkinson’s cell therapy.

Enhanced Production of Mesencephalic Dopaminergic Neurons from Lineage‑Restricted Human Undifferentiated Stem Cells. Maimaitili M, Chen M, Febbraro F, Ucuncu E, Kelly R, Niclis JC, Christiansen JR, Mermet-Joret N, Niculescu D, Lauritsen J, Iannielli A, Klæstrup IH, Jensen UB, Qvist P, Nabavi S, Broccoli V, Nykjær A, Romero-Ramos M, Denham M. Nature Communications (2023) https://doi.org/10.1038/s41467-023-43471-0

This publication introduces lineage‑restricted undifferentiated stem cells (LR‑USCs), engineered to prevent unwanted cell fates and enable controlled generation of authentic midbrain dopaminergic neurons. Compared to conventional pluripotent stem cell differentiation, LR‑USCs produced substantially higher yields of dopaminergic progenitors and mature neurons. In preclinical Parkinson’s models, LR‑USC–derived grafts demonstrated superior neuronal survival, robust graft formation, and complete restoration of motor function. These findings establish the scientific and translational basis of UniPotent’s therapeutic program.

How to Make a Midbrain Dopaminergic Neuron. Arenas E, Denham M, Villaescusa JC. Development (2015)

This widely cited work defined the core developmental pathways required to generate bona fide mesencephalic dopaminergic neurons in vitro. By clarifying the molecular logic of midbrain specification, the study provided a blueprint for producing clinically relevant dopaminergic cells and directly informed the engineering strategy underlying the LR‑USC platform.

GSK3β and Activin/Nodal Inhibition in Human Embryonic Stem Cells induces a Pre-neuroepithelial State that is required for Specification to a Floor Plate Cell Lineage. Denham M, Bye C, Leung J, Conley B, Thompson L, Dottori M. Stem Cells (2012)

This study established a controlled method to drive human pluripotent stem cells into a lineage‑competent intermediate state required for floor plate formation, a critical step in dopaminergic neuron development. The work demonstrated that precise pathway modulation can reproducibly direct early lineage commitment, a principle later embedded into lineage‑restricted stem cell design.

GLI1 is an Inducing Factor in Generating Floor Plate Progenitor Cells from Human Embryonic Stem Cells. Denham M, Thompson L, Leung J, Pébay A, Björklund A, Dottori M. Stem Cells (2010)

This publication demonstrated targeted induction of floor plate progenitors through defined molecular control of developmental signaling pathways. It provided early evidence that dopaminergic lineage intermediates can be generated reproducibly and specifically, supporting scalable therapeutic manufacturing.